title: Effect of CD14 blockade on endotoxin-induced acute lung injury in mice.
abstract: CD14 functions as a cell surface receptor for endotoxin (lipopolysaccharide [LPS]) and is thought to have an essential role in innate immune responses to infection. Previous studies have revealed attenuation of the systemic response after sepsis by blocking CD14. In this study, we tested the hypothesis that CD14 blockade protects against inflammatory responses associated with LPS pneumonia. We examined the effect of an anti-murine CD14 monoclonal antibody (4C1) on the development of acute lung injury induced by intratracheal LPS in mice. We also measured the production of cytokines (tumor necrosis factor-alpha, interleukin-6, and macrophage inflammatory protein-2) and nitric oxide by murine peritoneal macrophages exposed to LPS in vitro. Nuclear factor (NF)-kappa B translocation was evaluated in nuclear extracts from lung homogenates. 4C1 significantly attenuated pulmonary edema and neutrophil emigration after LPS administration. The production of cytokines and nitric oxide by LPS-stimulated macrophages was significantly decreased by 4C1 treatment. NF-kappa B translocation induced by LPS instillation was also suppressed by 4C1. These results suggest that blockade of CD14 might attenuate acute lung injury after intratracheal instillation of LPS through the suppression of NF-kappa B translocation. The inhibitory effect of CD14 blockade on cytokine production and nitric oxide release of macrophages might contribute to the attenuation of lung injury.
authors.affiliation: Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Sadatomo
authors.initials: S
authors.lastname: Tasaka
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Ishizaka
authors.forename: Wakako
authors.initials: W
authors.lastname: Yamada
authors.forename: Mie
authors.initials: M
authors.lastname: Shimizu
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Koh
authors.forename: Naoki
authors.initials: N
authors.lastname: Hasegawa
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Adachi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yamaguchi
mesh_terms: D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D054426:Chemokine CXCL2; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D015850:Interleukin-6 / Q000096:biosynthesis / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism; D008070:Lipopolysaccharides / Q000378:metabolism; D008168:Lung / Q000473:pathology*; D055370:Lung Injury; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D015846:Monokines / Q000096:biosynthesis; D016328:NF-kappa B / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D021381:Protein Transport; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000378:metabolism
chemical_list: D054426:Chemokine CXCL2; D004731:Endotoxins; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D015846:Monokines; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide